Compared to these efforts, our study uniquely focuses on the cancer-testis antigens DKKL1, FBXO39, and OIP5, which have been largely underexplored in CRC immunotherapy despite their selective overexpression and potent immunogenic potential. The gene discussed is FBXO39; the disease is cancer.